Compare Illumina, Inc. (ILMN) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Visa Inc — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while Visa Inc trades at $375.22 (market cap $698.56B). The key difference: Visa Inc is far larger — about 17.5× Illumina, Inc.'s market cap, and Visa Inc pays a 0.72% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Visa Inc for 115 Days on average.
| ILMN | V | |
|---|---|---|
Market Cap | $39.95B | $698.56B |
Volume | 3,169,503 | 4,446,146 |
Sector | Health | Financials |
52-Week High | $293.69 | $384.14 |
52-Week Low | $91.00 | $295.52 |
Typical Hold Time | 83 Days | 115 Days |
Enterprise Value | $41.31B | $709.14B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Visa (V) trades at $372.10, up 0.39% with a bullish technical outlook. The stock shows strong fundamentals with 85% analyst buy ratings and a $422.24 consensus price target, representing 13.5% upside. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.32 exceeding the $3.23 forecast. The company maintains exceptional profitability with 50.78% net margins and 61.79% ROE, while expanding AI-driven commerce initiatives through new partnerships and technology platforms.
Visa presents a compelling long-term investment case with dominant market position, consistent earnings growth, and strategic AI integration. Key risks include regulatory pressures, fintech competition, and stablecoin disruption potential. The current valuation at 31.67x P/E reflects premium pricing but is supported by strong growth prospects and defensive cash flow characteristics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
